Version imprimable
Bonjour,
Est-on obligé de prendre la dose de 1 Mg de finastéride/ jour ou peut-on descendre à 0.5 Mg voir 0.2 Mg.
Certains articles semblent suggérer que les dosages 0.5 et 0.2 ont presque les même effet que le 1 mg .
Un professionnel pour m'éclairer ?
Bien à vous,
Kurt.
La dose de 1 mg a été testé après des essais de doses ( l'article date de 1999), le voici - 0, 2 est efficace mais moins efficace que 1 mg alors que 5 mg n'est pas plus efficace que 1mg.
[SIZE=2]
[/SIZE][SIZE=2][URL="http://www.ncbi.nlm.nih.gov/pubmed/10495375#"]J Am Acad Dermatol.[/URL] 1999 Oct;41(4):555-63.[/SIZE]
[h=1][SIZE=2]Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss.[/SIZE][/h][SIZE=2][URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Roberts%20JL%22%5BAuthor%5D"]Roberts JL[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Fiedler%20V%22%5BAuthor%5D"]Fiedler V[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Imperato-McGinley%20J%22%5BAuthor%5D"]Imperato-McGinley J[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Whiting%20D%22%5BAuthor%5D"]Whiting D[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Olsen%20E%22%5BAuthor%5D"]Olsen E[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Shupack%20J%22%5BAuthor%5D"]Shupack J[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Stough%20D%22%5BAuthor%5D"]Stough D[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22DeVillez%20R%22%5BAuthor%5D"]DeVillez R[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Rietschel%20R%22%5BAuthor%5D"]Rietschel R[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Savin%20R%22%5BAuthor%5D"]Savin R[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bergfeld%20W%22%5BAuthor%5D"]Bergfeld W[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Swinehart%20J%22%5BAuthor%5D"]Swinehart J[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Funicella%20T%22%5BAuthor%5D"]Funicella T[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hordinsky%20M%22%5BAuthor%5D"]Hordinsky M[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lowe%20N%22%5BAuthor%5D"]Lowe N[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Katz%20I%22%5BAuthor%5D"]Katz I[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lucky%20A%22%5BAuthor%5D"]Lucky A[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Drake%20L%22%5BAuthor%5D"]Drake L[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Price%20VH%22%5BAuthor%5D"]Price VH[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Weiss%20D%22%5BAuthor%5D"]Weiss D[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Whitmore%20E%22%5BAuthor%5D"]Whitmore E[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Millikan%20L%22%5BAuthor%5D"]Millikan L[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Muller%20S%22%5BAuthor%5D"]Muller S[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Gencheff%20C%22%5BAuthor%5D"]Gencheff C[/URL], et al.[/SIZE]
[h=3][SIZE=2]Source[/SIZE][/h][SIZE=2]Northwest Cutaneous Research Specialists, Portland, Oregan, USA.[/SIZE]
[h=3][SIZE=2]Abstract[/SIZE][/h][h=4][SIZE=2]BACKGROUND: [/SIZE][/h][SIZE=2]Androgenetic alopecia is a common condition of adult men. Finasteride, a type 2 5alpha-reductase inhibitor, decreases the formation of dihydrotestosterone from testosterone.[/SIZE]
[h=4][SIZE=2]OBJECTIVE: [/SIZE][/h][SIZE=2]Two separate clinical studies were conducted to establish the optimal dose of finasteride in men with this condition.[/SIZE]
[h=4][SIZE=2]METHODS: [/SIZE][/h][SIZE=2]Men from 18 to 36 years of age with moderate vertex male pattern hair loss received finasteride 5, 1, 0.2, or 0.01 mg/day or placebo based on random assignment. Efficacy was determined by scalp hair counts, patient self-assessment, investigator assessment, and assessment of clinical photographs. Safety was assessed by clinical and laboratory measurements and by analysis of adverse experiences.[/SIZE]
[h=4][SIZE=2]RESULTS: [/SIZE][/h][SIZE=2]Efficacy was demonstrated for all end points for finasteride at doses of 0.2 mg/day or higher, with 1 and 5 mg demonstrating similar efficacy that was superior to lower doses. Efficacy of the 0.01 mg dose was similar to placebo. No significant safety issues were identified in the trials.[/SIZE]
[h=4][SIZE=2]CONCLUSION: [/SIZE][/h][SIZE=2]Finasteride 1 mg/day is the optimal dose for the treatment of men with male pattern hair loss and was subsequently identified for further clinical development.
[/SIZE]
[SIZE=2][/SIZE]
Bonjour ,
Merci pour votre réponse.
Mais qu'en est-il du dosage 0.5 Mg au lieu de 1 mg ?
Une question encore : Qu'en est-il de l'avodart ?
Bien à vous,
Kurt.